Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.37 |
| ▸ | FDPS | P14324 | 9/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10491876 | 1.00 | TSHR (0.40) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL15121126 | 1.00 | TSHR (0.40) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL9787912 | 1.00 | TSHR (0.40) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL9477891 | 1.00 | TSHR (0.40) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL10916892 | 0.97 | TSHR (0.38) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL6920148 | 0.90 | — | — | |
| SCHEMBL9478548 | 0.89 | — | — | |
| SCHEMBL13584591 | 0.85 | FDPS (0.35) | TSHRGGPS1FDPSSMPD1 | |
| SCHEMBL8763241 | 0.81 | — | — | |
| SCHEMBL12602517 | 0.81 | TSHR (0.40) | TSHRTHRBCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173704-A2 | PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE | BASF SE (DE) | 2010-04-14 | — | — | EP | claimed |
| WO-2009013199-A2 | PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE | BASF SE (DE) | 2009-01-29 | — | — | WO | claimed |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4442319-A2 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| EP-4081511-B1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2024-07-31 | — | — | EP | disclosed |
| CN-116178210-B | Preparation method of citronellyl nitrile derivative | 鹰潭华煜生物科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| EP-3656832-B1 | LIGAND-MODIFIED QUANTUM DOT COMPOSITION, LIGAND-MODIFIED QUANTUM DOT LAYER, PREPARATION METHOD THEREFOR, AND QUANTUM DOT LIGHT-EMITTING DIODE | BOE TECHNOLOGY GROUP CO LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-20090286815-A1 | Pyrimidine Classical Cannabinoid Compounds and Related Methods of Use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-11-19 | — | — | US | disclosed |
| US-20090286815-A1 | Pyrimidine Classical Cannabinoid Compounds and Related Methods of Use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-11-19 | — | — | US | disclosed |
| US-20090286818-A1 | Pyridine Non-Classical Cannabinoid Compounds and Related Methods of Use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-11-19 | — | — | US | disclosed |
| US-20090286818-A1 | Pyridine Non-Classical Cannabinoid Compounds and Related Methods of Use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-11-19 | — | — | US | disclosed |
| US-20090286824-A1 | Pyridine Classical Cannabinoid Compounds and Related Methods of Use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-11-19 | — | — | US | disclosed |
| US-20090286810-A1 | Pyrimidine Non-Classical Cannabinoid Compounds and Related Methods of Use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-11-19 | — | — | US | disclosed |
| US-20090286824-A1 | Pyridine Classical Cannabinoid Compounds and Related Methods of Use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-11-19 | — | — | US | disclosed |
| US-20090286810-A1 | Pyrimidine Non-Classical Cannabinoid Compounds and Related Methods of Use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-11-19 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213315-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | TSHR 131/4885THRB 232/4885GGPS1 1490/4885 |
| US-20090286824-A1 | Pyridine Classical Cannabinoid Compounds and Related Methods of Use | CNR1, CNR2, NPY1R | TSHR 753/4885THRB 1242/4885GGPS1 1399/4885 |
| US-20090286815-A1 | Pyrimidine Classical Cannabinoid Compounds and Related Methods of Use | CNR1, CNR2, GPR18 | TSHR 1075/4885THRB 976/4885GGPS1 387/4885 |
| US-20090286810-A1 | Pyrimidine Non-Classical Cannabinoid Compounds and Related Methods of Use | CNR1, CNR2, GPR18 | TSHR 964/4885THRB 851/4885GGPS1 341/4885 |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | TSHR 3550/4885THRB 4456/4885GGPS1 717/4885 |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TSHR 3443/4885THRB 3939/4885GGPS1 262/4885 |
| US-20090286818-A1 | Pyridine Non-Classical Cannabinoid Compounds and Related Methods of Use | CNR1, CNR2, NPY1R | TSHR 713/4885THRB 1376/4885GGPS1 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.